Bluejay Diagnostics, Inc. (BJDX)
NASDAQ: BJDX · Real-Time Price · USD
3.450
-0.080 (-2.27%)
At close: Feb 21, 2025, 4:00 PM
3.770
+0.320 (9.28%)
After-hours: Feb 21, 2025, 6:03 PM EST
Bluejay Diagnostics Employees
Bluejay Diagnostics had 10 employees as of December 31, 2023. The number of employees decreased by 6 or -37.50% compared to the previous year.
Employees
10
Change (1Y)
-6
Growth (1Y)
-37.50%
Revenue / Employee
n/a
Profits / Employee
-$858,855
Market Cap
1.85M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 10 | -6 | -37.50% |
| Dec 31, 2022 | 16 | 7 | 77.78% |
| Dec 31, 2021 | 9 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 89,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
BJDX News
- 3 months ago - Bluejay Diagnostics Announces Reverse Stock Split - GlobeNewsWire
- 8 months ago - Bluejay Diagnostics Announces Closing of $8.75 Million Underwritten Public Offering - GlobeNewsWire
- 8 months ago - SYMON-I Study of Symphony IL-6 Suggests Prediction of Mortality in Sepsis Patients - GlobeNewsWire
- 1 year ago - Bluejay Diagnostics Announces Closing of $3.5 Million Public Offering - GlobeNewsWire
- 1 year ago - Bluejay Diagnostics Announces Pricing of $3.5 Million Public Offering - GlobeNewsWire
- 1 year ago - Bluejay Diagnostics, Inc. Announces Initiation of Multicenter Clinical Study Evaluating Symphony IL-6 in Sepsis Patients (SYMON Study) - GlobeNewsWire
- 1 year ago - Bluejay Diagnostics, Inc. Reports Third Quarter 2023 Financial Results - GlobeNewsWire
- 1 year ago - Bluejay Diagnostics Announces $1.59 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules - GlobeNewsWire